ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02945176
Recruitment Status : Completed
First Posted : October 26, 2016
Last Update Posted : August 18, 2017
Sponsor:
Information provided by (Responsible Party):
Implandata Ophthalmic Products GmbH

Brief Summary:

The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely. It is intended to be used together with the hand-held Mesograph reading device to telemetrically measure the intraocular pressure (IOP) of patients with a BKPro.

The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in patients undergoing concomitant implantation of a BKPro and an ARGOS-IO sensor over the 12 month period beginning at implantation.


Condition or disease Intervention/treatment Phase
Graft vs Host Disease Congenital Aniridia Chemical Burns Stevens-Johnson Syndrome Congenital Glaucoma Device: ARGOS-IO system Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro)
Study Start Date : March 2015
Actual Primary Completion Date : June 14, 2017
Actual Study Completion Date : June 14, 2017


Arm Intervention/treatment
Experimental: ARGOS-IO system

The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.

Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation

Accessories: MESOGRAPH reading device, Implant Injector

Device: ARGOS-IO system
This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
Other Name: ARGOS-IO pressure sensor implant




Primary Outcome Measures :
  1. Safety of the ARGOS-IO pressure sensor in the first 12 months following implantation [ Time Frame: 12 months ]

    Number of subjects experiencing at any time during the first 12 months a device related serious adverse event (SAE) defined as any adverse event that both:

    is considered by the investigator to have a possible, probable or definite relationship to the device

    AND that leads to any following

    • death
    • a serious deterioration in the health of the subject that results in a life-threatening illness or injury or a permanent impairment of a body structure or function, or that requires medical/surgical intervention to prevent such
    • hospitalization or prolongation of existing hospitalization
    • fetal distress or death or a congenital abnormality or birth defect.

  2. Tolerability of the ARGOS-IO pressure sensor in the first 12 months following implantation [ Time Frame: 12 months ]

    Number of subjects experiencing at any time during the first 12 months a device related SAE defined as any adverse event that both:

    is considered by the investigator to have a possible, probable or definite relationship to the device

    AND that leads to any following

    • death
    • a serious deterioration in the health of the subject that results in a life-threatening illness or injury or a permanent impairment of a body structure or function, or that requires medical/surgical intervention to prevent such
    • hospitalization or prolongation of existing hospitalization
    • fetal distress or death or a congenital abnormality or birth defect.

  3. Performance of the ARGOS-IO system compared to manometry in the first 12 months following implantation [ Time Frame: 12 months ]
    Level of agreement between IOP measurements made using manometry (mmHg) and the ARGOS-IO system (mmHg) over the first 12 months following implantation


Secondary Outcome Measures :
  1. Safety of the ARGOS-IO pressure sensor use in the first 4, 16 and 28 weeks and 12 months following implantation [ Time Frame: 4, 16 and 28 weeks and 12 months following implantation ]
    Incidence, nature, seriousness, severity and duration of adverse events and adverse device events in the first 4, 16 and 28 weeks and 12 months following implantation of the ARGOS-IO pressure sensor.

  2. Tolerability of the ARGOS-IO pressure sensor use in the first 4, 16 and 28 weeks and 12 months following implantation [ Time Frame: 4, 16 and 28 weeks and 12 months following implantation ]
    Incidence, nature, seriousness, severity and duration of adverse events and adverse device events in the first 4, 16 and 28 weeks and 12 months following implantation of the ARGOS-IO pressure sensor.

  3. Level of agreement between IOP measurements made using surgical manometry (mmHg) and the ARGOS-IO system (mmHg) at 4, 16, 28 and 52 weeks following implantation [ Time Frame: 4, 16, 28 and 52 weeks following implantation ]
  4. User acceptance of the implantation procedure by means of evaluation of the implantation procedure questionnaire (investigators) [ Time Frame: 4, 16, 28 and 52 weeks following implantation ]
  5. User acceptance of the ARGOS-IO system at the investigational site by means of evaluation of the investigator acceptance questionnaire (investigators) [ Time Frame: 4, 16, 28 and 52 weeks following implantation ]
  6. Daily IOP self-measurement profiles (subjects) [ Time Frame: 4, 16, 28 and 52 weeks following implantation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female aged ≥ 18 and ≤ 80 years on the day of screening
  2. Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularized cornea AND either a verifiable history of two or more prior failed corneal transplant procedures or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
  3. Axial length > 21 mm
  4. Ability and willingness to attend all scheduled visits and comply with all study procedures

Exclusion Criteria:

  1. Reasonable chance of success with traditional keratoplasty
  2. Current retinal detachment
  3. Connective tissue diseases
  4. History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis, scleritis) in one or both eyes within 6 months prior to ARGOS-IO implantation
  5. History of ocular or periocular malignancy
  6. History of extensive keloid formation
  7. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, or silicone (component of the device)
  8. Presence of another active medical eye implant and/or other active medical implants in the head/neck region
  9. Signs of current infection, including fever and current treatment with antibiotics
  10. Severe generalized disease that results in a life expectancy shorter than a year
  11. Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device
  12. Currently pregnant or breastfeeding
  13. Participation in any study involving an investigational drug or device within the past 30 days or ongoing participation in a study with an investigational drug or device
  14. Intraoperative complication that would preclude implantation of the study device
  15. Subject and/or an immediate family member is an employee of the investigational site directly affiliated with this study, the sponsor or the contract research organization.

Previous or concurrent enrollment of the contralateral eye in this clinical study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02945176


Locations
Germany
Zentrum für Augenheilkunde der Universität zu Köln
Cologne, Germany, 50924
MVZ Prof. Neuhann
Munich, Germany, 80637
Sponsors and Collaborators
Implandata Ophthalmic Products GmbH
Investigators
Principal Investigator: Thomas Neuhann, Prof. MD MVZ Prof. Neuhann

Responsible Party: Implandata Ophthalmic Products GmbH
ClinicalTrials.gov Identifier: NCT02945176     History of Changes
Other Study ID Numbers: ARGOS-KP01
CIV-14-09-012725 ( Registry Identifier: EUDAMED )
First Posted: October 26, 2016    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Implandata Ophthalmic Products GmbH:
Boston Keratoprosthesis

Additional relevant MeSH terms:
Graft vs Host Disease
Stevens-Johnson Syndrome
Aniridia
Hydrophthalmos
Burns, Chemical
Immune System Diseases
Stomatitis
Mouth Diseases
Stomatognathic Diseases
Drug Eruptions
Dermatitis
Skin Diseases
Erythema Multiforme
Erythema
Skin Diseases, Vesiculobullous
Drug Hypersensitivity
Hypersensitivity
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Eye Abnormalities
Eye Diseases
Eye Diseases, Hereditary
Iris Diseases
Uveal Diseases
Congenital Abnormalities
Genetic Diseases, Inborn
Glaucoma, Open-Angle
Glaucoma
Ocular Hypertension
Infant, Newborn, Diseases